Keywords: positive, ph, ii, data, novartis, fty720, swiss
Positive Ph II data for Novartis
Article | 27 June 2005
Swiss drug major Novartis' candidate treatment for multiple sclerosis, FTY720, a novel, once-daily, oral medication, reduced the rate of clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
